JB 101
Alternative Names: JB-101; Transplant rejection cell therapy - Kidswell BioLatest Information Update: 10 Nov 2023
At a glance
- Originator Gene Techno Science
- Developer JUNTEN BIO; Juntendo University
- Class Cell therapies; T lymphocyte cell therapies
- Mechanism of Action Cell replacements; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Transplant rejection